Anastrozole Tablet
Product Images NDC 43063-383

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 43063-383). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

43063383 Label (43063383)

Label for Anastrozole 1 mg tablets, oral dosage form, in a package containing 15 tablets. The label shows the NDC 43063-383-15, is marked for RX use only, and includes a warning to keep out of reach of children. The product is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. Additional details include lot D19E11 and expiration date 04/2021.*

FDA Label Image

Anastrozole 01

Chemical structure of anastrozole, showing the molecular arrangement including a triazole ring attached to a benzene ring with methyl and cyano substituents.*

FDA Label Image

Anastrozole 02

A line chart comparing disease-free survival over 90 months between anastrozole and tamoxifen treatments. The vertical axis shows the proportion of patients alive and disease-free, while the horizontal axis shows disease-free survival time in months. The graph includes patient counts at risk for both treatments at various time points along the bottom.*

FDA Label Image

Anastrozole 03

A line chart depicting disease-free survival over time in months, comparing two randomized treatments: anastrozole (dashed line) and tamoxifen (solid line). The y-axis shows the proportion of patients alive and disease-free, ranging from 0 to 1. The x-axis covers disease-free survival in months, from 0 to 90. Below the x-axis, the number of patients at risk is listed at various time points for both treatments.*

FDA Label Image

Anastrozole 04

A Kaplan-Meier survival curve chart comparing the proportion event-free over 120 months for two randomized treatments: Anastrozole (solid line) and Tamoxifen (dashed line). The x-axis represents time to event in months, and the y-axis shows the proportion event-free. Below the curves, the number of patients at risk is displayed at various time points up to 120 months.*

FDA Label Image

Anastrozole 05

A Kaplan-Meier survival curve chart comparing the proportion of event-free patients over time (in months) for Anastrozole versus Tamoxifen treatments. The x-axis represents time to event in months up to 120 months, and the y-axis represents the proportion event free, ranging from 0.50 to 1.00. A table below lists the number of patients at risk at specific time points for both treatments.*

FDA Label Image

Anastrozole 06

A line graph comparing the proportion of patients not progressing over time (in months) between two randomized treatments: Anastrozole and Tamoxifen. The x-axis represents time to progression in months from 0 to 42, and the y-axis shows the proportion not progressing from 0.0 to 1.0. Patient counts at risk are indicated below the x-axis for various months.*

FDA Label Image

Anastrozole 07

A Kaplan-Meier survival curve comparing time to progression (months) between two randomized treatments, Anastrozole (solid line) and Tamoxifen (dashed line). The y-axis shows the proportion not progressing, and the x-axis is time in months. A risk table below indicates patient counts at various time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.